CLINICAL_TRIALS
trial_result
· 2020-08-03
Clinical Trial Update: Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease [Phase 2]
Summary
Phase 2 clinical study of CDP870 (Certolizumab Pegol) in active Crohn's disease has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: UCB Pharma | Conditions: Crohn's Disease | Phase 2 | Status: COMPLETED | Results posted: 2020-08-03